<DOC>
	<DOCNO>NCT01736514</DOCNO>
	<brief_summary>This multicenter , open label , randomize , allopurinol-controlled , parallel-design study . Approximately 120 subject randomly assign 1:1 ratio receive febuxostat , allopurinol subject gout .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Oral Febuxostat Patients With Gout</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Subjects also history presence gout define American College Rheumatology ( ACR ) criterion Subject serum urate level &gt; = 8.0 mg/dL screen Visit Female subject breastfeeding pregnant Subject history xanthinuria Subject intolerant allopurinol , ie hypersensitivity , StevenJohnson syndrome/topic epidermal necrolysis Subject take allopurinol &gt; 300 mg/day serum urate level &gt; 8mg/dL Subject HLA B*5801 positive Subject receive thiazide diuretic therapy Subject secondary hyperuricemia Subject require concurrent therapy systemic topical medication , prescribe nonprescribed , contain aspirin salicylate ( low dos aspirin allow ( ie . = &lt; 325mg/day ) Subject require therapy prednisone &gt; 10 mg/ day study Subject active liver disease hepatic dysfunction , define ALT AST &gt; 1.5 time upper limit normal Subject serum creatinine &gt; = 1.5mg/dL Subject another significant medical condition define investigator would interfere treatment , safety compliance protocol ( eg . A clinically significant ECG result ) Subject history cancer ( basal cell carcinoma skin ) within 5 year prior study , take systemic cancer chemotherapy within 5 year prior study Subject previously participate clinical study febuxostat administer Subject participate another investigational trial within 30 day prior study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>xanthine oxidase inhibitor</keyword>
	<keyword>Uric acid lower drug</keyword>
</DOC>